Trademark Search in Canada

ITM

View On IC.GC.CA

REGISTERED

on 16 Nov 2022

TM5 Status

LIVE/REGISTRATION/Issued and Active

Your registration has been issued and is active. You can now use the TM5 mark.

Last Applicant/ Owned by

ITM ISOTOPE TECHNOLOGIES MUNICH SE

Lichtenbergstr. 185748 Garching

Serial Number

2057595 filed on 28^th Jul 2020

Registration Number

TMA1151987 registered on 16^th Nov 2022

Registration expiry Date

28^th Jul 2030

Correspondent Address

OYEN WIGGS GREEN & MUTALA LLP

480-THE STATION, 601 WEST CORDOVA STREETVANCOUVER

BRITISH COLUMBIA

V6B1G1

ITM

Trademark usage description

radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide Read More

Classification Information

Class [005]
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely lutetium-containing precursors; solutions for radioactive labelling; radiopharmaceutical preparations for use in oncology, namely radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases.

Classification kind code

Class [010]
Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; apparatus and containers with radiotherapeutic and radiodiagnostic substances for use in diagnosis and treatment in field of oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies; radionuclide generators for radiopharmaceutical purposes

Classification kind code

Class [042]
Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET].

Classification kind code

Class [044]
Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.

Classification kind code

Mark Details

Serial Number

2057595

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 22 on 25^th Jan 2022	Search Recorded
Submitted for opposition 48 on 7^th Jan 2022	Agent Changed
Submitted for opposition 135 on 24^th Nov 2021	Amendment to Application
Submitted for opposition 256 on 16^th Aug 2021	Notification of Possible Opposition Sent
Submitted for opposition 48 on 9^th Dec 2020	Agent Changed
Submitted for opposition 257 on 15^th Oct 2020	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 15^th Oct 2020	Formalized
Submitted for opposition 1 on 15^th Oct 2020	Created
Submitted for opposition 228 on 28^th Jul 2020	International Registration
Submitted for opposition 30 on 28^th Jul 2020	Filed

ITM

Classification Information

Classification kind code

Classification kind code

Class [042]Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET].

Classification kind code

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [042]
Conducting clinical trials at all stages and in various indications, particularly in oncology; conducting phase III clinical trials with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET].